Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network
Atezo-bev was used as 1L systemic therapy for HCC in a diverse patient population across US community oncology settings. Real-world effectiveness of atezo-bev among trial-like patients is comparable to that reported in the Phase 3 study. These data can help guide selection of appropriate treatment candidates and maximize the benefits of atezo-bev in routine clinical practice.
Authors
- Amit G. Singal (ORCID: https://orcid.org/0000-0002-1172-3971)
- David Cosgrove (ORCID: https://orcid.org/0000-0003-2700-5656)
- Sarika Ogale
- Andrew J. Osterland (ORCID: https://orcid.org/0000-0003-4488-0604)
- Thomas W. Wilson (ORCID: https://orcid.org/0000-0002-5282-4023)
- Arturo Loaiza‐Bonilla (ORCID: https://orcid.org/0000-0002-3655-9602)
- Ruoding Tan (ORCID: https://orcid.org/0000-0002-3547-4156)
- Gregory Patton
- Sami Mahrus
- John Murphy (ORCID: https://orcid.org/0000-0003-0723-3475)
- Sairy Hernandez
Institutions
- AIR Worldwide (United States) (US)
- The US Oncology Network (US)
- Capital Health (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/jhc.s492881
- Citations
- 4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 5.29